150986-62-2

Basic information

• Product Name: N-BOC-(3R,4R)-3,4-PYRROLIDINEDIOL
• Synonyms: N-BOC-(3R,4R)-3,4-PYRROLIDINEDIOL;(3R,4R)-1-Boc-pyrrolidine-3,4-diol;(3R,4R)-1-(tert-Butoxycarbonyl)-3,4-dihydroxypyrrolidine;tert-butyl-(3R,4R)-dihydroxypyrrolidine-1-carboxylate;tert-butyl (3R,4R)-3,4-dihydroxypyrrolidine-1-carboxylate;(3R,4R)-tert-Butyl 3,4-dihydroxypyrrolidine-1-carboxylate
• CAS NO: 150986-62-2
• Molecular Formula: C₉H₁₇NO₄
• Molecular Weight: 203.24
• Mol File: 150986-62-2.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 300.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.262±0.06 g/cm3(Predicted)
• PKA: 13.91±0.40(Predicted)
• CAS DataBase Reference: N-BOC-(3R,4R)-3,4-PYRROLIDINEDIOL(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-(3R,4R)-3,4-PYRROLIDINEDIOL(150986-62-2)
• EPA Substance Registry System: N-BOC-(3R,4R)-3,4-PYRROLIDINEDIOL(150986-62-2)

Safety Data

• Hazardous Substances Data: 150986-62-2(Hazardous Substances Data)

Usage

General Description

N-BOC-(3R,4R)-3,4-pyrrolidinediol is a chemical compound that belongs to the class of BOC-protected amino alcohols. It is commonly used as a reagent in organic synthesis and as a building block for the preparation of various pharmaceuticals and natural products. N-BOC-(3R,4R)-3,4-PYRROLIDINEDIOL is known for its stereochemical purity, with the (3R,4R) configuration providing specific properties and reactivity in chemical reactions. The BOC protecting group is used to prevent unwanted reactions and to enable selective functionalization of the hydroxyl group. Overall, N-BOC-(3R,4R)-3,4-pyrrolidinediol is a valuable chemical intermediate that plays a crucial role in the synthesis of complex organic molecules.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 163439-82-5 (3R,4R)-1-benzyl-3,4-pyrrolidinediol 
• 186393-31-7 (3R,4R)-pyrrolidine-3,4-diol 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 1428671-12-8 (3S,4S)-1-(tert-butoxycarbonyl)-3,4-pyrrolidinediyl diacetate 
• 762-75-4 tert-butyl formate 
• 90481-32-6 (3S,4S)-pyrrolidine-3,4-diol 
• 90365-74-5 (3S,4S)-(+)-1-benzyl-3,4-pyrrolidinediol 

Downstream Products

• 1374429-77-2 (3R,4S)-tert-butyl 3-azido-4-(bis(4-methoxyphenyl)(phenyl)methoxy)pyrrolidine-1-carboxylate 
• 1412256-91-7 (3R,4S)-tert-butyl 3-(benzyloxycarbonylamino)-4-(bis(4-methoxyphenyl)(phenyl)methoxy)pyrrolidine-1-carboxylate 
• 1193318-61-4 (3S,4R)-4-amino-1-N-Boc-3-dimethoxytrityloxypyrrolidine 
• 694439-03-7 tert-butyl (4aS,7aS)-hexahydro-6H-[1,4]dioxino[2,3-c]pyrrolidine-6-carboxylate 
• 372482-11-6 tert-butyl (3S,4S)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 148214-86-2 tert-butyl (3R,4R)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 276862-76-1 (3S,4S)-pyrrolidine-3,4-diol hydrochloride 

Relevant articles and documents

Selective Isomerization via Transient Thermodynamic Control: Dynamic Epimerization of trans to cis Diols

Traditional approaches to stereoselective synthesis require high levels of enantio- and diastereocontrol in every step that forms a new stereocenter. Here, we report an alternative approach, in which the stereochemistry of organic substrates is selectivel

Compounds with higher PKG (protein kinase G) inhibitory activity and preparation method of compounds

The invention discloses compounds which have higher PKG (protein kinase G) inhibitory activity and are represented as a formula I, pharmaceutically acceptable salts, pharmaceutical composition containing the novel compounds, as well as an application of the novel compounds in treatment of pain, especially chronic pain. The invention further discloses a preparation method of the compounds and new intermediates. R1 and R2 are the same or different and are selected from a group comprising halogen (such as F or Cl), C1-C6 alkoxy, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl; R3 is a terminal group and is selected from a group comprising H, halogen, alkyl, naphthenic base, alkenyl, alkynyl, aryl and heteroaryl; n is the number of repetitive units and is an integer in a range from 1 to 15.

PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyrazolo[1,5-a]pyrimidine-5,7- diamine compounds (referred to herein as "PPDA compounds") that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK; and to treat disorders including: disorders that are associated with CDK; disorders that result from an inappropriate activity of a cyclin-dependent kinase (CDK); disorders that are associated with CDK mutation; disorders that are associated with CDK overexpression; disorders that are associated with upstream pathway activation of CDK; disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; and cardiovascular disorders (including atherosclerosis). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.